title: Contribution of monocytes to the decreased lymphoproliferative response to phytohemagglutinin in patients with lung cancer.
abstract: Patients with lung cancer (LC) have a reduced T-cell proliferative response to phytohemagglutinin (PHA) compared with that of healthy individuals. This decreased response is a result of an inhibitory effect exerted by the monocytes as evidenced by: (1) a restoration to normal levels of the response to PHA when the peripheral blood mononuclear cells were depleted of adherent cells (AD) and (2) a dose-dependent inhibition of the response to PHA when the nonadherent cell population was co-cultured with increasing numbers of autologous AD cells. The addition of indomethacin to the cultures resulted in only a partial restoration of the response to PHA. Monocyte production of interleukin-1 from patients with LC in response to lipopolysaccharide was normal. These findings support the hypothesis that the AD cell population plays a major role in the low T-cell proliferative response to PHA in patients with LC. This suppressor effect is partially mediated by the prostaglandins released by the monocytes.
authors.affiliation: Department of Internal Medicine, Hospital Nacional Marqués de Valdecilla, Facultad de Medicina, Universidad de Cantabria, Santander, Spain.
authors.forename: M C
authors.initials: MC
authors.lastname: Fariñas
authors.forename: V
authors.initials: V
authors.lastname: Rodriguez-Valverde
authors.forename: M T
authors.initials: MT
authors.lastname: Zarrabeitia
authors.forename: J A
authors.initials: JA
authors.lastname: Parra-Blanco
authors.forename: J
authors.initials: J
authors.lastname: Sanz-Ortiz
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology; D000368:Aged; D002277:Carcinoma / Q000276:immunology / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D007375:Interleukin-1 / Q000096:biosynthesis; D008175:Lung Neoplasms / Q000276:immunology* / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology*; D009367:Neoplasm Staging; D010835:Phytohemagglutinins; D013491:Suppressor Factors, Immunologic / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D007375:Interleukin-1; D010835:Phytohemagglutinins; D013491:Suppressor Factors, Immunologic; D007213:Indomethacin